Literature DB >> 22722201

The landscape of cancer genes and mutational processes in breast cancer.

Philip J Stephens1, Patrick S Tarpey, Helen Davies, Peter Van Loo, Chris Greenman, David C Wedge, Serena Nik-Zainal, Sancha Martin, Ignacio Varela, Graham R Bignell, Lucy R Yates, Elli Papaemmanuil, David Beare, Adam Butler, Angela Cheverton, John Gamble, Jonathan Hinton, Mingming Jia, Alagu Jayakumar, David Jones, Calli Latimer, King Wai Lau, Stuart McLaren, David J McBride, Andrew Menzies, Laura Mudie, Keiran Raine, Roland Rad, Michael Spencer Chapman, Jon Teague, Douglas Easton, Anita Langerød, Ming Ta Michael Lee, Chen-Yang Shen, Benita Tan Kiat Tee, Bernice Wong Huimin, Annegien Broeks, Ana Cristina Vargas, Gulisa Turashvili, John Martens, Aquila Fatima, Penelope Miron, Suet-Feung Chin, Gilles Thomas, Sandrine Boyault, Odette Mariani, Sunil R Lakhani, Marc van de Vijver, Laura van 't Veer, John Foekens, Christine Desmedt, Christos Sotiriou, Andrew Tutt, Carlos Caldas, Jorge S Reis-Filho, Samuel A J R Aparicio, Anne Vincent Salomon, Anne-Lise Børresen-Dale, Andrea L Richardson, Peter J Campbell, P Andrew Futreal, Michael R Stratton.   

Abstract

All cancers carry somatic mutations in their genomes. A subset, known as driver mutations, confer clonal selective advantage on cancer cells and are causally implicated in oncogenesis, and the remainder are passenger mutations. The driver mutations and mutational processes operative in breast cancer have not yet been comprehensively explored. Here we examine the genomes of 100 tumours for somatic copy number changes and mutations in the coding exons of protein-coding genes. The number of somatic mutations varied markedly between individual tumours. We found strong correlations between mutation number, age at which cancer was diagnosed and cancer histological grade, and observed multiple mutational signatures, including one present in about ten per cent of tumours characterized by numerous mutations of cytosine at TpC dinucleotides. Driver mutations were identified in several new cancer genes including AKT2, ARID1B, CASP8, CDKN1B, MAP3K1, MAP3K13, NCOR1, SMARCD1 and TBX3. Among the 100 tumours, we found driver mutations in at least 40 cancer genes and 73 different combinations of mutated cancer genes. The results highlight the substantial genetic diversity underlying this common disease.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22722201      PMCID: PMC3428862          DOI: 10.1038/nature11017

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  32 in total

1.  Mutations in human TBX3 alter limb, apocrine and genital development in ulnar-mammary syndrome.

Authors:  M Bamshad; R C Lin; D J Law; W C Watkins; P A Krakowiak; M E Moore; P Franceschini; R Lala; L B Holmes; T C Gebuhr; B G Bruneau; A Schinzel; J G Seidman; C E Seidman; L B Jorde
Journal:  Nat Genet       Date:  1997-07       Impact factor: 38.330

2.  Allele-specific copy number analysis of tumors.

Authors:  Peter Van Loo; Silje H Nordgard; Ole Christian Lingjærde; Hege G Russnes; Inga H Rye; Wei Sun; Victor J Weigman; Peter Marynen; Anders Zetterberg; Bjørn Naume; Charles M Perou; Anne-Lise Børresen-Dale; Vessela N Kristensen
Journal:  Proc Natl Acad Sci U S A       Date:  2010-09-13       Impact factor: 11.205

3.  Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma.

Authors:  Siân Jones; Tian-Li Wang; Ie-Ming Shih; Tsui-Lien Mao; Kentaro Nakayama; Richard Roden; Ruth Glas; Dennis Slamon; Luis A Diaz; Bert Vogelstein; Kenneth W Kinzler; Victor E Velculescu; Nickolas Papadopoulos
Journal:  Science       Date:  2010-09-08       Impact factor: 47.728

4.  Akt (protein kinase B) negatively regulates SEK1 by means of protein phosphorylation.

Authors:  Hee-Sae Park; Mi-Sung Kim; Sung-Ho Huh; Jihyun Park; Jongkyeong Chung; Sang Sun Kang; Eui-Ju Choi
Journal:  J Biol Chem       Date:  2001-11-13       Impact factor: 5.157

Review 5.  Genome-wide association studies in common cancers--what have we learnt?

Authors:  Jajini Susan Varghese; Douglas F Easton
Journal:  Curr Opin Genet Dev       Date:  2010-04-24       Impact factor: 5.578

Review 6.  Oncogenic transformation and experimental models of human cancer.

Authors:  Anna C Schinzel; William C Hahn
Journal:  Front Biosci       Date:  2008-01-01

Review 7.  Transcription-coupled nucleotide excision repair in mammalian cells: molecular mechanisms and biological effects.

Authors:  Maria Fousteri; Leon H F Mullenders
Journal:  Cell Res       Date:  2008-01       Impact factor: 25.617

Review 8.  Eukaryotic nucleotide excision repair: from understanding mechanisms to influencing biology.

Authors:  Sarah C Shuck; Emily A Short; John J Turchi
Journal:  Cell Res       Date:  2008-01       Impact factor: 25.617

Review 9.  The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications.

Authors:  Amancio Carnero; Carmen Blanco-Aparicio; Oliver Renner; Wolfgang Link; Juan F M Leal
Journal:  Curr Cancer Drug Targets       Date:  2008-05       Impact factor: 3.428

10.  A transforming mutation in the pleckstrin homology domain of AKT1 in cancer.

Authors:  John D Carpten; Andrew L Faber; Candice Horn; Gregory P Donoho; Stephen L Briggs; Christiane M Robbins; Galen Hostetter; Sophie Boguslawski; Tracy Y Moses; Stephanie Savage; Mark Uhlik; Aimin Lin; Jian Du; Yue-Wei Qian; Douglas J Zeckner; Greg Tucker-Kellogg; Jeffrey Touchman; Ketan Patel; Spyro Mousses; Michael Bittner; Richard Schevitz; Mei-Huei T Lai; Kerry L Blanchard; James E Thomas
Journal:  Nature       Date:  2007-07-04       Impact factor: 69.504

View more
  776 in total

1.  Genomics: the breast cancer landscape.

Authors:  Joe Gray; Brian Druker
Journal:  Nature       Date:  2012-06-20       Impact factor: 49.962

2.  SDPR functions as a metastasis suppressor in breast cancer by promoting apoptosis.

Authors:  Sait Ozturk; Panagiotis Papageorgis; Chen Khuan Wong; Arthur W Lambert; Hamid M Abdolmaleky; Arunthathi Thiagalingam; Herbert T Cohen; Sam Thiagalingam
Journal:  Proc Natl Acad Sci U S A       Date:  2016-01-06       Impact factor: 11.205

Review 3.  Practicing pathology in the era of big data and personalized medicine.

Authors:  Jiang Gu; Clive R Taylor
Journal:  Appl Immunohistochem Mol Morphol       Date:  2014-01

Review 4.  Collection, integration and analysis of cancer genomic profiles: from data to insight.

Authors:  Jianjiong Gao; Giovanni Ciriello; Chris Sander; Nikolaus Schultz
Journal:  Curr Opin Genet Dev       Date:  2014-02-27       Impact factor: 5.578

5.  APOBEC3B is an enzymatic source of mutation in breast cancer.

Authors:  Michael B Burns; Lela Lackey; Michael A Carpenter; Anurag Rathore; Allison M Land; Brandon Leonard; Eric W Refsland; Delshanee Kotandeniya; Natalia Tretyakova; Jason B Nikas; Douglas Yee; Nuri A Temiz; Duncan E Donohue; Rebecca M McDougle; William L Brown; Emily K Law; Reuben S Harris
Journal:  Nature       Date:  2013-02-06       Impact factor: 49.962

6.  Coexisting genomic aberrations associated with lymph node metastasis in breast cancer.

Authors:  Li Bao; Zhaoyang Qian; Maria B Lyng; Ling Wang; Yuan Yu; Ting Wang; Xiuqing Zhang; Huanming Yang; Nils Brünner; Jun Wang; Henrik J Ditzel
Journal:  J Clin Invest       Date:  2018-04-23       Impact factor: 14.808

Review 7.  AKT/PKB Signaling: Navigating the Network.

Authors:  Brendan D Manning; Alex Toker
Journal:  Cell       Date:  2017-04-20       Impact factor: 41.582

Review 8.  High-throughput gene expression and mutation profiling: current methods and future perspectives.

Authors:  Thomas Karn
Journal:  Breast Care (Basel)       Date:  2013-12       Impact factor: 2.860

9.  Genome-wide analysis of alternative transcripts in human breast cancer.

Authors:  Ji Wen; Kevin H Toomer; Zhibin Chen; Xiaodong Cai
Journal:  Breast Cancer Res Treat       Date:  2015-04-26       Impact factor: 4.872

10.  NRMT2 is an N-terminal monomethylase that primes for its homologue NRMT1.

Authors:  Janusz J Petkowski; Lindsay A Bonsignore; John G Tooley; Daniel W Wilkey; Michael L Merchant; Ian G Macara; Christine E Schaner Tooley
Journal:  Biochem J       Date:  2013-12-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.